Status:
COMPLETED
HFNC Treatment in COVID-19 Pneumonia
Lead Sponsor:
Sisli Hamidiye Etfal Training and Research Hospital
Conditions:
Coronavirus Infection
Pneumonia, Viral
Eligibility:
All Genders
18+ years
Brief Summary
coronavirus disease 2019 related pneumonia is causing acute respiratory failure and this is the most common reason for ICU admission. We have several different way for respiratory support. HFNC is one...
Detailed Description
In the first group (group H), the data of patients undergoing HFNC treatment, and in group II (Group K), the data of patients who received COT with a reservoir mask were included. In HFNC support, th...
Eligibility Criteria
Inclusion
- We include the patient with acute respiratory failure related coronavirus disease 2019 (diagnosed with polymerase Chain Reaction), older than 18 year and supported by High Flow Nasal cannulae or conventional oxygen treatment(COT).
Exclusion
- Patients with primary pulmonary disease, Glasgow Coma scale≤ 12 , respiratory acidosis in the first blood gases(ph≤ 7,2 - pCO2≥50) will exclude.
Key Trial Info
Start Date :
May 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 5 2020
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04424836
Start Date
May 15 2020
End Date
June 5 2020
Last Update
July 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sisli Etfal Research and Training Hospital
Istanbul, Turkey (Türkiye), 34371